Abstract 3258
Background
New therapeutic concepts have led to substantial improvement in the survival of cancer patients. Yet, due to their compromised immune system these patients are at increased risk to encounter infections and need particular care with regard to vaccine preventable diseases (VPDs). Decreased seroprevalence to VPDs has already been reported in children suffering from malignancies, yet data from adult cancer patients are scarce. Here, we examined the antibody (Ab) titers as well as seronegativity levels against common VPDs in adults with cancer and compared them to healthy controls.
Methods
Abs mounted against measles, mumps, rubella, varicella, hepatitis A and B, diphtheria, tetanus, pertussis and tick-borne encephalitis (TBE) were evaluated in sera from 478 cancer patients and 117 age- and gender-matched controls by standard ELISAs.
Results
Compared to controls, significantly lower Ab levels against 5 out of the 10 investigated VPDs (p < 0.05), i.e. measles, hepatitis B, diphtheria, tetanus and TBE, were found in patients with solid cancers (SC), while patients with haematological cancers (HC) had significantly lower antibody titers against all 10 examined VPDs (p < 0.05). In accordance, compared to controls, cancer patients had increased seronegativity rates against VPDs, of which those against diphtheria (41% in SC patients and 76% in HC patients), hepatitis B (74% in SC patients and 87% in HC patients) and pertussis (75% in SC patients and 91% in HC patients) were the highest.
Conclusions
Patients with SC and HC have lower antibody titers and higher seronegativity rates against the most common VPDs compared to the general population. Thus, in order to prevent severe infections in this patient group, the vaccination status as well as vaccination programs need to be routinely implemented into oncological treatment concepts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ursula Wiedermann.
Funding
Institute of Specific Prophylaxis and Tropical Medicine, Medical University of Vienna.
Disclosure
A.S. Berghoff: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Daiichi Sankyo; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy: Bristol-Meyers Squibb; Honoraria (self), Advisory / Consultancy: Merck; Travel / Accommodation / Expenses: Amgen; Travel / Accommodation / Expenses: AbbVie. C.C. Zielinski: Honoraria (self), Advisory / Consultancy, Member of scientific advisory board until September 2018: Imugene; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), institution: Central European Cooperative Oncology Oncology Group (CECOG): BMS; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), institution: Central European Cooperative Oncology Oncology Group (CECOG): MSD; Honoraria (self), Advisory / Consultancy: Ariad; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), institution: Central European Cooperative Oncology Oncology Group (CECOG): Pfizer; Honoraria (self), Advisory / Consultancy: Merrimack; Honoraria (self), Advisory / Consultancy: Merck KGaA; Honoraria (self), Advisory / Consultancy: Fibrogen; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), institution: Central European Cooperative Oncology Oncology Group (CECOG): AstraZeneca; Honoraria (self), Advisory / Consultancy: Tesaro; Honoraria (self), Advisory / Consultancy: Gilead; Honoraria (self), Advisory / Consultancy: Servier; Honoraria (self), Advisory / Consultancy: Shire; Honoraria (self), Advisory / Consultancy: Eli Lilly; Honoraria (self), Advisory / Consultancy: Athenex. U. Wiedermann: Research grant / Funding (institution), Officer / Board of Directors, CSO until October 2018: Imugene; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): GSK; Research grant / Funding (institution): Themis. All other authors have declared no conflicts of interest.
Resources from the same session
592 - Effects of novel targeted anticancer drugs on cytotoxicity, apoptosis, angiogenesis, EMT, drug resistance and autophagic mechanism
Presenter: Seyma Aydinlik
Session: Poster Display session 1
Resources:
Abstract
3235 - Delineating the mechanisms of alpha 1-3 fucosyltransferase FUT11 in ovarian cancer
Presenter: Qi Chen
Session: Poster Display session 1
Resources:
Abstract
3577 - The tyrosine kinase inhibitor Dasatinib blocks tumor growth, invasion and recurrence potential by interrupting the communication between cancer cells and their surrounding microenvironment in triple negative breast cancer
Presenter: Miriam Nuncia-Cantarero
Session: Poster Display session 1
Resources:
Abstract
4808 - NORE1A induces a feedback termination of TNF signaling by antagonizing TNFR1 through ITCH-mediated destruction complex
Presenter: Jieun Ahn
Session: Poster Display session 1
Resources:
Abstract
1294 - Hsp90 inhibitors enhance the antitumoral effect of osimertinib and overcome osimertinib resistance in non-small-cell cell lung cancer cell models
Presenter: Jordi Codony-Servat
Session: Poster Display session 1
Resources:
Abstract
1559 - Expression of IL-17RA promotes cancer stem-like properties of colorectal cancer cells by Stat3 activation
Presenter: Chih-Yung Yang
Session: Poster Display session 1
Resources:
Abstract
1615 - Adaption of Pancreatic Cancer Cells to AKT1 Inhibition Induces the Acquisition of Cancer Stem-Cell Like Phenotype Through Upregulation of Mitochondrial Functions
Presenter: Hugo Arasanz
Session: Poster Display session 1
Resources:
Abstract
4793 - Bub3 is phosphorylated by the Ataxia-Telangiectasia Mutated Kinase in mitosis and required for activation of the mitotic spindle checkpoint in Breast Cancer
Presenter: Mingming Xiao
Session: Poster Display session 1
Resources:
Abstract
1448 - The regulation of INK4 locus by long non-coding RNAs
Presenter: Yojiro Kotake
Session: Poster Display session 1
Resources:
Abstract
1858 - Vascular Endothelial Growth Factor in Colorectal Cancer Pathology, Survival and Treatment
Presenter: Liz Baker
Session: Poster Display session 1
Resources:
Abstract